The Tobira Therapeutics Inc. (TBRA) Downgraded by Zacks Investment Research

The Tobira Therapeutics Inc. (TBRA) Downgraded by Zacks Investment Research

Zacks Investment Research cut shares of Tobira Therapeutics Inc. (NASDAQ:TBRA) from a hold rating to a sell rating in a research note published on Saturday morning.

According to Zacks, “Tobira Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapies to treat liver disease, inflammation, liver fibrosis and human immunodeficiency virus. Tobira Therapeutics, Inc., formerly known as Regado Biosciences, Inc., is headquartered in San Francisco, CA. “

A number of other brokerages have also recently weighed in on TBRA. HC Wainwright reiterated a buy rating on shares of Tobira Therapeutics in a report on Tuesday, June 28th. Cantor Fitzgerald cut Tobira Therapeutics from a buy rating to a hold rating and lifted their target price for the company from $19.00 to $42.00 in a report on Wednesday, September 21st. Mizuho reiterated a buy rating and issued a $305.00 target price on shares of Tobira Therapeutics in a report on Thursday, September 22nd. Finally, Cowen and Company reiterated a buy rating and issued a $11.00 target price on shares of Tobira Therapeutics in a report on Wednesday, August 10th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average target price of $68.63.

Tobira Therapeutics (NASDAQ:TBRA) opened at 40.21 on Friday. The stock’s 50 day moving average price is $23.82 and its 200 day moving average price is $12.32. The firm’s market capitalization is $756.79 million. Tobira Therapeutics has a 52-week low of $3.76 and a 52-week high of $41.39.

Tobira Therapeutics (NASDAQ:TBRA) last issued its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.63) by $0.08. The company earned $1.06 million during the quarter. Analysts expect that Tobira Therapeutics will post ($2.65) earnings per share for the current year.

In related news, major shareholder Pentwater Capital Management L acquired 100,000 shares of the business’s stock in a transaction on Friday, September 23rd. The shares were bought at an average cost of $39.19 per share, with a total value of $3,919,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 6.20% of the stock is owned by company insiders.

Hedge funds have recently made changes to their positions in the company. Havens Advisors LLC acquired a new stake in shares of Tobira Therapeutics during the third quarter worth about $119,000. Schwab Charles Investment Management Inc. acquired a new stake in shares of Tobira Therapeutics during the second quarter worth about $177,000. Teachers Advisors Inc. raised its stake in shares of Tobira Therapeutics by 287.1% in the second quarter. Teachers Advisors Inc. now owns 14,484 shares of the biopharmaceutical company’s stock worth $182,000 after buying an additional 10,742 shares during the last quarter. California State Teachers Retirement System raised its stake in shares of Tobira Therapeutics by 230.2% in the second quarter. California State Teachers Retirement System now owns 18,578 shares of the biopharmaceutical company’s stock worth $233,000 after buying an additional 12,951 shares during the last quarter. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Tobira Therapeutics during the second quarter worth about $263,000. 62.02% of the stock is currently owned by institutional investors and hedge funds.

Tobira Therapeutics Company Profile

Tobira Therapeutics, Inc, formerly Regado Biosciences, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and human immunodeficiency virus (HIV). The Company’s lead product candidate, cenicriviroc (CVC), is an immunomodulator and dual inhibitor of C-C Chemokine Receptor 2 (CCR2) and C-C Chemokine Receptor 5 (CCR5) being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and as an adjunctive therapy to standard of care in HIV.

Related posts

Leave a Comment